ECOGRAFIA CON MDC (CEUS) E ECO-COLOR DOPPLER VASCOLARE: DALLE LINEEGUIDA ALLA PRATICA CLINICA

1. 1.Aboyans V, RiccoJB, Bartelink MELet al.. 2017 ECS guidelines on the diagnosis andtreatment of peripheral arterial disease, incollaboration with the European Society ofVascular Surgery (ESVS).. ur Heart J 2018; 39(9):763-816. DOI:10.1093/eurheartj/ehx095. PMID: 288866. 2018
   Articolo scientificour Heart J 2018; 39(9):763-816. DOI:10.1093/eurheartj/ehx095. PMID: 288866Cerca su Google Scholar
2. 2.Palareti G et al.. Design and rationale of a randomized,placebo-controlled trial on the efficacy andsafety of sulodexide for extended treatment inelderly patients after a first venousthromboembolism. Intern Emerg Med. 2021 Mar;16(2):359-368. doi:10.1007/s11739-020-02381-5. Epub 2020 May 25.PMID: 32451933; PMCID: PMC7952285. 2021
   Articolo scientificoIntern Emerg Med. 2021 Mar;16(2):359-368. doi:10.1007/s11739-020-02381-5. Epub 2020 May 25.PMID: 32451933; PMCID: PMC7952285Cerca su Google Scholar
3. 3.Stevens SM et al.. Antithrombotic Therapy for VTE Disease:Second Update of the CHEST Guideline andExpert Panel Report. Chest. 2021 Aug 2:S0012-3692(21)01506-3. doi:10.1016/j.chest.2021.07.055. PMID: 34352278. 2021
   Articolo scientificoChest. 2021 Aug 2:S0012-3692(21)01506-3. doi:10.1016/j.chest.2021.07.055. PMID: 34352278Leggi il PDF gratuito
4. 4.Beyer-Westendorf J,Schellong SM,Gerlach H, et al. Prevention of thromboembolic complications inpatients with superficial-vein thrombosis givenrivaroxaban or fondaparinux: the openlabel,randomised, non-inferiority SURPRISE phase3b trial.. The Lancet Haematology 2017; 4:e 105-e113. 2017
   Articolo scientificoThe Lancet Haematology 2017; 4:e 105-e113Leggi il paperCerca versione gratuita
5. 5.Eikelboom JW,Connolly SJ,Yusuf S.. Rivaroxaban in Stable Cardiovascular Disease. N Engl J Med 2018; 378: 397-8.. 2018
   Articolo scientificoN Engl J Med 2018; 378: 397-8.Cerca su Google Scholar
6. 6.Kaplovitch E,Eikelboom JW,Dyal L et al.. Rivaroxaban and aspirin in patients withsymptomatic lower extremity peropheralartery disease. A subanalysis of the COMPASSrandomized trial. Jama Cardiol. 2021;6(1):21-29.DOI:10.1001/jamacardio.2020.439. 2021
   Articolo scientificoJama Cardiol. 2021;6(1):21-29.DOI:10.1001/jamacardio.2020.439Cerca su Google Scholar

I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).